An undisclosed drug risk lawsuit occurs when a pharmaceutical manufacturer fails to adequately warn patients or healthcare providers about known or knowable dangers associated with a medication, and people are harmed as a result. These lawsuits allege that drug companies withheld critical safety information, concealed research about side effects, or downplayed risks to protect profits—allowing consumers to take medications without full knowledge of potential consequences. As of 2026, thousands of undisclosed drug risk cases are active across the United States, with some of the largest concentrations involving GLP-1 weight-loss drugs like Ozempic and Wegovy, which face over 4,400 lawsuits alleging failure to warn about stomach paralysis and intestinal damage.
The legal basis for these cases typically rests on two theories: failure to warn (the company knew or should have known about a risk but failed to communicate it) and fraudulent concealment (the company actively hid information). When pharmaceutical companies have access to safety data—whether from their own research, clinical trials, or post-market surveillance—they have a legal obligation to disclose those risks in labeling and to healthcare providers. Failure to do so can expose them to significant liability, and plaintiffs injured by undisclosed risks can pursue compensation for medical expenses, lost wages, pain and suffering, and sometimes punitive damages.
Table of Contents
- What Are the Most Common Undisclosed Drug Risks in Current Litigation?
- How Does Failure to Warn Work in Drug Litigation?
- Real-World Examples of Undisclosed Drug Risks
- How Are Damages Calculated in Undisclosed Drug Risk Cases?
- What Challenges Do Plaintiffs Face in Proving Undisclosed Risks?
- The Role of FDA Oversight and Post-Market Surveillance
- What Happens Next for Undisclosed Drug Risk Litigation?
- Conclusion
What Are the Most Common Undisclosed Drug Risks in Current Litigation?
The most active undisclosed drug risk litigation in 2024-2026 centers on medications with newly recognized or inadequately disclosed dangers. GLP-1 receptor agonists—a class of drugs originally developed for type 2 diabetes and now marketed for weight loss—have become the focal point of pharmaceutical litigation. Novo Nordisk’s Ozempic and Wegovy, along with Eli Lilly’s Mounjaro, face accusations that manufacturers failed to adequately warn patients about gastroparesis (stomach paralysis) and severe intestinal complications. As of May 2026, more than 1,800 people have filed suit against these manufacturers, with 2,914 cases pending in consolidated litigation as of November 2025.
The settlement range for these cases is estimated between $400,000 and $700,000 per plaintiff, depending on the severity of injury and individual circumstances. Beyond weight-loss drugs, other recent undisclosed risk cases involve medications across different therapeutic categories. Depo-Provera, the injectable birth control product made by Pfizer, became the subject of litigation after a March 2024 study linked the contraceptive to meningioma—a type of brain tumor affecting the meninges (the membrane surrounding the brain and spinal cord). Lawsuits allege that Pfizer failed to warn women and their doctors about the increased risk, depriving patients of the opportunity to make informed choices about contraception. Similarly, Oxbryta, a medication for sickle cell disease, faces allegations that its manufacturer failed to warn patients about vaso-occlusive crises—painful blockages in blood vessels—with the first class action trial scheduled for August 2027.
How Does Failure to Warn Work in Drug Litigation?
pharmaceutical failure to warn claims differ from general product liability in that the manufacturer’s duty centers on communication rather than the product’s inherent design. Under U.S. pharmaceutical law, a company must warn about risks that were known or reasonably knowable at the time of sale. This includes risks identified in clinical trials, post-market surveillance reports, medical literature, and adverse event reports submitted to the FDA. The warning must reach not only patients but also healthcare providers who prescribe the medication, and the information must be proportionate to the risk—serious, life-altering side effects require more prominent warnings than minor effects. One limitation in these cases is that plaintiffs often must prove they would have chosen differently (refused the medication or chosen an alternative) had the warning been properly disclosed.
If a patient cannot establish they would have made a different decision, some courts limit their recovery even if the failure to warn is proven. The opioid litigation offers a cautionary precedent. Purdue Pharma, manufacturer of OxyContin, faced massive liability for failure to warn about addiction risks and for allegedly downplaying opioid dangers to doctors. In January 2025, the company reached a settlement agreement valued at $7.4 billion, with the Sackler family (company owners) committing to pay up to $6.5 billion over 15 years. The Purdue case illustrates both the scale of potential liability and the prolonged nature of pharmaceutical litigation—cases took years to develop and resolve. However, a critical downside for plaintiffs in opioid cases was that many settlements had per-claim caps or per-state limitations, meaning individual victims recovered less than initially estimated when the total settlement was divided among all claimants.
Real-World Examples of Undisclosed Drug Risks
Risperdal, an antipsychotic medication made by Janssen Pharmaceuticals, demonstrates how undisclosed risks in pediatric use can trigger mass litigation. Risperdal was prescribed off-label to children for conditions like autism, ADHD, and behavioral disorders, yet the manufacturer allegedly failed to adequately warn about gynecomastia (breast tissue growth in males), metabolic effects, and movement disorders. Most Risperdal lawsuits settled in 2024, with families reporting that their sons developed significant breast tissue growth and other endocrine complications. These cases were particularly compelling because the drug was prescribed to children who could not consent to the risk, raising the moral stakes and making juries sympathetic to plaintiffs.
The GLP-1 litigation evolving in 2026 provides a contemporary example of how undisclosed risks emerge even for medications with FDA approval. When Ozempic and Wegovy were approved and marketed, their labeling included general gastrointestinal warnings, but patients and some healthcare providers report that the specific risk of gastroparesis—a potentially irreversible condition—was not clearly communicated. Some patients have required surgery or developed permanent digestive dysfunction, alleging they never would have used the medication had they known this risk existed. The litigation reflects a broader pattern: FDA approval means a drug is safe enough to market, not that all risks are known or disclosed, and post-market evidence can reveal problems that require legal accountability.
How Are Damages Calculated in Undisclosed Drug Risk Cases?
Damages in undisclosed drug risk lawsuits typically include economic losses (medical bills, ongoing treatment costs, lost income) and non-economic damages (pain and suffering, loss of enjoyment of life, emotional distress). In the GLP-1 litigation, settlement estimates of $400,000 to $700,000 per case reflect the severity of injuries—gastroparesis can require multiple surgeries, ongoing nutritional support, and permanently impaired quality of life. By contrast, Risperdal cases often settled for lower amounts because while gynecomastia is distressing, it can sometimes be surgically corrected, and economic losses are typically lower. The comparison illustrates how courts and settlement negotiators weigh both the permanence of injury and its financial impact.
Punitive damages—additional money designed to punish a company for egregious conduct—are available in some undisclosed drug risk cases but not all. A company that deliberately concealed safety data faces higher punitive exposure than one that made a reasonable error in assessment. However, many cases settle before trial, and settlement agreements often do not include public disclosure of the precise terms or the reasoning, making it difficult for future plaintiffs to predict what their case might be worth. The tradeoff is between certainty (a settlement guarantees payment without trial risk) and potential reward (trials can yield punitive damages but carry the risk of losing entirely).
What Challenges Do Plaintiffs Face in Proving Undisclosed Risks?
One of the biggest obstacles in undisclosed drug risk cases is establishing causation—proving that the drug actually caused the injury and that it wasn’t something else entirely. For medications used by large populations, distinguishing between side effects and coincidental health problems requires medical evidence, expert testimony, and sometimes epidemiological studies. A limitation that courts often impose is that plaintiffs must show the risk was both undisclosed and that they would not have used the medication had the risk been properly communicated. If a patient testifies that they would have taken the drug anyway despite the risk, their claim fails—even if the failure to warn is proven.
This puts the burden on plaintiffs to reconstruct their decision-making from years or decades prior. Another challenge is the statute of limitations—the legal deadline for filing a lawsuit. In many states, claims must be filed within two to four years of discovering the injury, though some states allow longer periods for “discovery rule” cases where the injury wasn’t immediately apparent. For example, a woman taking Depo-Provera might develop a meningioma years after she stopped using the contraceptive, and by the time a causal link is established through research, the deadline for filing may have passed. A warning: patients who suspect they may have experienced a drug-related injury should consult a lawyer promptly rather than waiting for definitive scientific proof, as delay risks losing the right to sue entirely.
The Role of FDA Oversight and Post-Market Surveillance
The FDA’s role in drug safety creates both protection and complication for plaintiffs. The FDA requires pharmaceutical companies to submit adverse event reports (collected through healthcare providers, patients, and internal research), and the agency can issue stronger warnings or even withdraw approval if safety problems emerge.
However, the FDA’s regulatory actions are separate from private litigation, and a drug can remain on the market with inadequate warnings for years before regulatory action occurs. In some cases, lawsuits move faster than FDA processes—the GLP-1 litigation developed rapidly in 2025-2026 even as the FDA was still evaluating whether stronger warnings were necessary. An example: patients began reporting gastroparesis in online forums and through adverse event databases before a formal class action consolidated, meaning the medical community and patients discovered the risk through experience rather than through FDA mandates.
What Happens Next for Undisclosed Drug Risk Litigation?
As of 2026, undisclosed drug risk litigation continues to expand, with new cases emerging as post-market evidence reveals risks not apparent during initial FDA approval. The GLP-1 litigation will likely continue growing through 2027, and settlement discussions are ongoing, though no global settlement has been announced.
The Oxbryta case, with its first trial scheduled for August 2027, may establish precedent for how courts evaluate undisclosed risks in rare disease medications where the patient population is smaller but injuries are severe. The pattern suggests that pharmaceutical companies face increasing pressure to disclose emerging risks quickly and comprehensively, as social media and direct patient communication now allow safety signals to spread faster than ever before. Future litigation may hinge on whether companies waited too long to update warnings despite accumulating evidence of harm.
Conclusion
Undisclosed drug risk lawsuits represent a critical mechanism for holding pharmaceutical companies accountable when they fail to communicate known or knowable dangers. Whether the case involves weight-loss drugs, contraceptives, psychiatric medications, or rare disease therapies, the legal principle remains constant: patients have the right to make informed decisions about their medical treatment, and companies have the obligation to provide truthful, complete safety information.
The current wave of litigation—from GLP-1 drugs to Depo-Provera to Oxbryta—demonstrates that even FDA-approved medications can hide serious risks, and patients injured by those undisclosed risks can pursue meaningful compensation. If you believe you or a family member has been harmed by a medication due to inadequate warnings, documenting your medical history, gathering all prescription records, and consulting with a lawyer experienced in pharmaceutical litigation is essential. Time limits apply to these claims, and the sooner you connect with legal counsel, the better positioned you are to pursue compensation and ensure your experience contributes to holding companies accountable.